[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350733-105":59,"doc-detail-350733-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lactylation-of-mutation-prone-ras-residues-mimics-oncogenic-mutations-and-drives-constitutive-activation","Lactylation of Mutation-Prone RAS Residues Mimics Oncogenic Mutations and Drives Constitutive Activation","","Elevated wild-type RAS expression can promote tumorigenesis, but mutation-independent hyperactivity mechanisms remain unclear. This study investigates whether lactylation of RAS at specific residues drives constitutive activation. Mass spectrometry identifies lactylation sites, and a site-specific lactylation system introduces lactyl-lysine into RAS at K117 and K147. The work shows TIP60 catalyzes lactylation and SIRT2 reverses it, impairing GTP interaction and GTPase activity while stabilizing RAS by antagonizing K48-linked ubiquitination. Lactylation phenocopies oncogenic mutations, enhances malignant transformation, correlates with poor breast cancer prognosis, and creates therapeutic vulnerability to lactate-lowering strategies combined with MEK inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lactylation-of-mutation-prone-ras-residues-mimics-oncogenic-mutations-and-drives-constitutive-activation/350733/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lactylation-of-mutation-prone-ras-residues-mimics-oncogenic-mutations-and-drives-constitutive-activation/350733.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about wild-type RAS hyperactivity?","Question",{"text":112,"@type":113},"It tests whether lactylation of RAS at specific residues can drive constitutive activation without requiring cancer mutations, clarifying mechanisms behind mutation-independent hyperactivity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which residues of RAS are reported as lactylated and linked to cancer mutations?",{"text":117,"@type":113},"RAS is reported to be lactylated at K117 and K147, which are mutation-prone residues found in cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How does RAS lactylation mechanistically promote constitutive activation?",{"text":121,"@type":113},"Lactylation disrupts GTP interaction, impairs intrinsic GTPase activity, and antagonizes K48-linked ubiquitination at K147, stabilizing RAS and recapitulating effects of oncogenic mutations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350733,1790193450,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","ORIGINAL ARTICLE  \nLactylation of Mutation-Prone RAS Residues Mimics Oncogenic Mutations and Drives Constitutive Activation  \nRuocen Liao1,2†, Chenglong Ma1†, Xingyu Chen3†, Longchang Bai1†, Qianhua Cao3, Yu Zhang1, and Chenfang Dong1,2*  \n1Department of Surgical Oncology (Breast Center) and Department of Pathology and Pathophysiology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China. 2Department of Breast Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China. 3Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, P. R. China.  \n*Address correspondence to: [chenfangdong@zju.edu.cn](chenfangdong@zju.edu.cn)  \n†These authors contributed equally to this work.  \nBackground: Elevated expression of wild-type RAS contributes to tumorigenesis, yet the mechanisms underlying its mutation-independent hyperactivity remain unclear. Lactylation, a lactate-derived posttranslational modification, has emerged as a regulator in cancer, but its role in RAS activation is unknown. Here, we investigated whether lactylation of RAS at specific residues drives its constitutive activation and the underlying mechanisms. Methods: Lactylation sites on RAS were identified by mass spectrometry. A site-specific lactylation system was employed to introduce lactyl-lysine into RAS at K117 and K147. Structural effects were analyzed via molecular dynamics simulations. RAS activity was assessed through GTP-binding and GTPase assays; protein stability was evaluated using ubiquitination mutants and cycloheximide chase. The responsible enzymes were defined by in vitro lactylation and delactylation assays. Functional impact was tested via colony formation, mammosphere assays, and xenograft models. Clinical relevance was examined in breast cancer tissues and survival databases, and drug synergy was assessed by combining lactate-lowering agents with MEK inhibitors. Results: We reported that RAS was lactylated at K117 and K147, 2 residues mutated in cancers. Mechanistically, RAS lactylation was catalyzed by TIP60 and reversed by SIRT2 . Lactylation at these residues recapitulated features of oncogenic mutations by disrupting GTP interaction, impairing intrinsic guanosine triphosphatase (GTPase) activity, and competitively antagonizing K48-linked ubiquitination at K147 to stabilize RAS. Functionally, RAS lactylation promoted malignant transformation and tumorigenesis, phenocopying oncogenic mutations at the same sites. Inhibition of lactate production sensitized lactylated RAS-driven cancer cells to drugs targeting RAS mutations, revealing a therapeutic vulnerability. Clinically, RAS lactylation was elevated in breast cancer tissues and correlated with poor prognosis. Employing a site-specific lactylation system, we further confirmed that lactylation alone phenocopied mutation-driven RAS activation. Conclusions: Our study redefines lactylation as a functional“mutation mimic”mechanism, which not only recapitulates the effects of oncogenic mutations but also bridges the gap between genetic and epigenetic drivers in cancer. This suggests that targeting the lactylation pathway alone or in combination with mutation-directed therapies represents a promising strategy for treating wild-type RAS-driven cancers.  \nCitation: Liao R, MaC, Chen X, Bai L, Cao Q, Zhang Y, Dong C. Lactylation of Mutation-Prone RAS Residues Mimics Oncogenic Mutations and Drives Constitutive Activation. Cancer Commun. 2026;46:Article 0047. [https://doi.org/10.34133/](https://doi.org/10.34133/)[ ](https://doi.org/10.34133/)[cancomm.0047](cancomm.0047)  \nSubmitted 4 January 2026  \nRevised 24 July 2026  \nAccepted 11 August 2026  \nPublished 26 August 2026  \nCopyright © 2026 Ruocen Liao et al. Exclusive licensee","cbCaihT3mMlLpQyX","https://ap.wps.com/l/cbCaihT3mMlLpQyX","pdf",17419178,17,"English","# Background\n## RAS as a molecular switch and activation pathways\n## Oncogenic RAS mutations and wild-type RAS hyperactivation\n# Lactylation and study rationale\n# Methods\n## Identifying lactylation sites\n## Site-specific lactylation and structural analysis\n## Assessing activity, stability, and enzymes\n## Functional and clinical validation\n# Results\n## RAS lactylation at K117 and K147\n## TIP60 and SIRT2 control lactylation\n## Mechanistic mimicry of oncogenic mutations\n## Effects on transformation, tumorigenesis, and therapy response\n## Clinical relevance and prognosis association\n# Conclusions","[{\"question\":\"What question does the study address about wild-type RAS hyperactivity?\",\"answer\":\"It tests whether lactylation of RAS at specific residues can drive constitutive activation without requiring cancer mutations, clarifying mechanisms behind mutation-independent hyperactivity.\"},{\"question\":\"Which residues of RAS are reported as lactylated and linked to cancer mutations?\",\"answer\":\"RAS is reported to be lactylated at K117 and K147, which are mutation-prone residues found in cancers.\"},{\"question\":\"How does RAS lactylation mechanistically promote constitutive activation?\",\"answer\":\"Lactylation disrupts GTP interaction, impairs intrinsic GTPase activity, and antagonizes K48-linked ubiquitination at K147, stabilizing RAS and recapitulating effects of oncogenic mutations.\"}]","Lactylation of Mutation-Prone RAS Residues Mimics Oncogenic Mutations and Drives Constitutive Activation | PDF",1790090806,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd546a3fab8815df98874236eeddf34b.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20fb203e291fb7bab0ee6bb3c13d6ebe.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5bcf0e6e3e9c8c47570ed9160f2ef22.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a64bf86f804a77b5ba700301ca267b0e.webp",980,1306]